EcoVadis Rating validates Avantor's business sustainability commitments and performanceRADNOR, Pa., Sept. 12, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, announced today, for the second year in a row, that the Company has been awarded a Bronze Medal from EcoVadis, a global leader in business sustainability assessments.Avantor's latest score of 65, which was awarded ...

RADNOR, Pa., Aug. 22, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on Thursday, September 5, at approximately 10:45 a.m. Eastern Daylight Time.To hear a live audio webcast of the session, visit Even ...

Avantor, Inc. (AVTR) recently signed a definitive agreement to divest its clinical services business, including kitting, biorepository, and related equipment and ancillaries (collectively known as Clinical Services), to Audax Private Equity (Audax). The transaction is expected to close in the fourth quarter of 2024, subject to regulatory approvals and other customary closing conditions.The clinical services business is currently part of Avantor's Laboratory Solutions segment.Avantor’s management plans to di ...

Accelerates ongoing business transformation and sharpens Avantor's strategic focus Strengthens balance sheet with proceeds to be used for debt paydownRADNOR, Pa., Aug. 16, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the signing of a definitive agreement to divest its clinical services business, including kitting, biorepository, and related equipment ...

Core Viewpoint - Avantor, Inc. reported a decline in adjusted earnings per share (EPS) for Q2 2024, but the results exceeded consensus estimates despite a drop in revenue and segmental sales [1][2][9]. Revenue Details - Revenues for Q2 2024 totaled $1.7 billion, reflecting a year-over-year decrease of 2.4% and missing the Zacks Consensus Estimate [2]. - Foreign currency translation negatively impacted revenues by 0.4%, leading to an organic sales decline of 2% [2]. Segmental Analysis - Avantor restructured its reporting segments into two: Laboratory Solutions and Bioscience Production, effective January 1, 2024 [3]. - Laboratory Solutions reported net sales of $1.16 billion, down 3.2% year over year, with organic sales falling 2.7% due to inventory destocking and cautious spending by biopharma customers [3]. - Bioscience Production's net sales were $547.1 million, a decrease of 0.5% year over year, with organic sales down 0.3% [3]. Margin Analysis - Gross profit for the quarter declined 1.4% to $581.5 million, while gross margin expanded by 30 basis points to 34.1% [5]. - Selling, general, and administrative expenses increased by 13.5% year over year to $405.7 million [5]. - Operating profit rose significantly by 145.2% to $175.8 million, although the operating margin contracted by 620 basis points to 10.32% [5]. Financial Position - At the end of Q2 2024, Avantor had cash and cash equivalents of $272.6 million, up from $234.9 million at the end of Q1 [6]. - Total debt decreased to $5.12 billion from $5.3 billion at the end of Q1 2024 [6]. - Net cash provided by operating activities was $281.1 million, compared to $168.2 million a year ago [6]. Guidance - Avantor maintained its 2024 revenue outlook, projecting between $6.85 billion and $7.06 billion, which represents a decline of 1.7% to an increase of 1.3% from 2023 levels [7]. - The company expects organic revenues to decline by 2% to increase by 1% for the full year, with a similar expectation for Q3 [8]. - Adjusted EPS is projected to be between 96 cents and $1.04 for the full year, with the consensus estimate at $1 [8]. Additional Insights - Avantor's commercial intensity led to share gains through new contract wins and expanded customer relationships in various markets [4]. - The company launched several innovative products aimed at enhancing gene therapy processes and opened a new customer service center in Mexico to improve service levels [10]. - Avantor remains committed to sustainability, as evidenced by its annual sustainability report and ongoing cost transformation initiatives [11].

Avantor, Inc. AVTR reported better-than-expected second-quarter earnings results on Friday.Avantor posted adjusted earnings of 25 cents per share, beating market estimates of 23 cents per share. The company posted sales of $1.703 billion, in-line with estimates, according to data from Benzinga Pro.“Our teams delivered another solid quarter with sequential improvements to all key financial metrics. Improved mix from increased bioprocessing revenue together with the accelerated impact of our cost transformati ...

(Vavantor™ Q2 2024 Earnings EARNINGS PRESENTATION July 26, 2024 AVTR LISTED NYSE Disclaimer This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this presentation are forward-looking statements. Forward-looking s ...

Avantor Inc. (NYSE:AVTR) Q2 2024 Earnings Conference Call July 26, 2024 8:00 AM ET Company Participants Christina Jones - VP, IR Michael Stubblefield - President & CEO Brent Jones - EVP & CFO Conference Call Participants Vijay Kumar - Evercore ISI Tycho Peterson - Jefferies Douglas Schenkel - Wolfe Research Daniel Brennan - TD Cowen Rachel Vatnsdal - JPMorgan Michael Ryskin - Bank of America Jack Meehan - Nephron Research Matthew Sykes - Goldman Sachs Conor McNamara - RBC Capital Markets Luke Sergott - Barc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ━━━━━━━━━ FORM 10-Q ━━━━━━━━━ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-38912 Avantor, Inc. (Exact name of registrant as specified in its charter) Delaware 82-2758923 (Stat ...

Avantor, Inc. (AVTR) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.70%. A quarter ago, it was expected that this company would post earnings of $0.20 per share when it actually produced earnings of $0.22, delivering a surprise of 10%.Over the last four quarters, the company has su ...